共载阿霉素和依克立达的PLGA纳米粒的制备及表征

陈大中; 高洁; 解方园; 张翮; 鲁莹; 邹豪; 钟延强

doi:10.3969/j.issn.1006-0111.2017.03.007

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

《药学实践与服务》杂志目前不收取审稿费、版面费、加急费等费用，如收到邮件声称是编辑部X编辑，要求加作者微信的，请谨防财产损失！编辑部用于作者校对时绑定微信的邮件通过yxsjzzs@163.com发送，标题是《药学实践与服务》XML数字出版服务微信绑定，请区分开。

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

陈大中, 高洁, 解方园, 张翮, 鲁莹, 邹豪, 钟延强

文章导航 > 药学实践与服务 > 2017 > 35(3): 219-223,251

郝少君, 吕宏迪, 李军, 苏峰, 张正臣. 心脑宁片对大鼠血瘀模型的影响[J]. 药学实践与服务, 2014, 32(5): 360-361,388. doi: 10.3969/j.issn.1006-0111.2014.05.012

引用本文:

陈大中, 高洁, 解方园, 张翮, 鲁莹, 邹豪, 钟延强. 共载阿霉素和依克立达的PLGA纳米粒的制备及表征[J]. 药学实践与服务, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007

HAO Shaojun, LV Hongdi, LI Jun, SU Feng, ZHANG Zhengchen. Effect of Xinnaoning tablet on blood stasis model in rats[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 360-361,388. doi: 10.3969/j.issn.1006-0111.2014.05.012

Citation:

CHEN Dazhong, GAO Jie, XIE Fangyuan, ZHANG He, LU Ying, ZOU Hao, ZHONG Yanqiang. Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

doi: 10.3969/j.issn.1006-0111.2017.03.007

第二军医大学药学院, 上海 200433

基金项目: 国家自然科学基金资助项目（81573376）

Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

摘要: 目的建立药物测定方法，并制备共载阿霉素和依克立达的PLGA纳米粒。方法利用紫外分光光度法（UV）和高效液相色谱法（HPLC）分别建立阿霉素和依克立达的测定方法；采用纳米沉淀法制备共载纳米粒，通过调节两药的投药比，优化处方，考察纳米粒的粒径、形态、包封率、载药量以及体外释放。结果阿霉素在1~40 μg/ml浓度范围内线性关系良好，标准曲线回归方程为A=0.021C+0.002，r=0.999 5；依克立达在0.5~100 μg/ml浓度范围内线性关系良好，标准曲线回归方程为A=120 742.462 6C+1 974.570 4，r=1.000 0；通过处方优化，共载纳米粒的粒径约为50 nm，分布均一，呈圆形，阿霉素和依克立达的包封率分别为56.58%、51.66%，载药量分别为1.48%、1.85%，两药摩尔比约为1：1；体外释放缓慢。结论分别建立了方便快捷、结果准确、重复性好的阿霉素和依克立达的检测方法，并且制备了分散性好、粒径较小的纳米粒，为后续实验提供基础。
- 阿霉素 /
- 依克立达 /
- 纳米粒 /
- 紫外分光光度法 /
- 高效液相色谱法
Abstract: Objective To establish methods for the determination of doxorubicin and elacridar, and prepare PLGA nanoparticles for the co-delivery of doxorubicin and elacridar. Methods Ultraviolet spectrophotometry (UV) and high performance liquid chromatography (HPLC) were used to establish the determination method of doxorubicin and elacridar, respectively; co-delivery nanoparticles system was prepared by nanoprecipitation method, and optimizing the prescription was by adjusting the dosage ratio of the two drugs to investigate the particle size,morphology, encapsulation efficiency (EE), drug loading (DL) and in vitro release. Results The linearity of doxorubicin was better in the rang of 1 to 40 μg/ml, A=0.021C+0.002,r=0.999 5;the linearity of elacridar was better in the rang of 0.5 to 100 μg/ml,A=120 742.462 6C+1 974.570 4,r=1.000 0;the particle size was about 50 nm; transmission electron microscope (TEM) showed that nanoparticles were round in shape and had a good dispersion;EE of doxorubicin and elacridar were 56.58%、51.66%,respectively, DL of doxorubicin and elacridar were 1.48%、1.85%,respectively,the molar ratio of two drugs was about 1:1;the nanoparticles released slowly in vitro. Conclusion The established methods of doxorubicin and elacridar were convenient and efficient, accurate and repeatable.The Co-delivery nanoparticles system was well dispersionand smaller size, which could be used for further studies.
- doxorubicin /
- elacridar /
- nanoparticles /
- UV /
- HPLC

[1]	Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001,414(6859):105-111.
[2]	Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138(4):645-659.
[3]	Cojoc M, Mäbert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms[J]. Semin Cancer Biol, 2014, 31:16-27.
[4]	Hubensack M, Müller C, Höcherl P, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice[J]. J Cancer Res Clin Oncol, 2008, 134(5): 597-607.
[5]	Karla PK, Earla R, Boddu SH, et al. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells[J]. Curr Eye Res, 2009, 34(1): 1-9.
[6]	Nieto Montesinos RM, Beduneau A, Lamprecht A, et al. Liposomes co-loaded with elacridar and tariquidar to modulate the P-glycoprotein at the blood-brain barrier[J]. Mol Pharm, 2015, 12(11):3829-3838.
[7]	Wong HL, Bendayan R, Rauth AM, et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer[J]. J Control Release, 2006, 116(3):275-284.
[8]	Singh MS, Lamprecht A. Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin[J]. Int J Pharm, 2015, 478(2):745-752.
[9]	Planting AST,Sonneveld P,Gaast AVD,et al.A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors[J].Cancer Chemother Pharmacol,2005,55(1):91-99.
[10]	Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery[J]. Biomaterials, 2007, 28(5):869-876.
[11]	Zhu H, Chen H, Zeng X, et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance[J]. Biomaterials, 2013, 35(7):2391-2400.

[1]	张俊丽, 李媛媛, 尹静, 杨鸿源, 白耀武. 咪达唑仑调节PINK1/PARKIN信号通路对缺血性脑卒中大鼠神经元损伤的影响 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202405024
[2]	吴海韵, 杨甜, 张弛, 梁文仪, 苏娟. 气相色谱-离子迁移谱技术在中药研究中的应用进展 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202409007
[3]	姚小静, 计佩影, 陆峰, 施国荣, 傅翔. 表面增强拉曼光谱法快速测定尿液中曲马多的研究 . 药学实践与服务, 2025, 43(4): 1-5. doi: 10.12206/j.issn.2097-2024.202401072
[4]	肖农, 陆诗依, 唐文雅, 居敏俐, 徐刚锋, 杨明华. 中成药微生物计数法前处理的影响因素和优化方法 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202403014
[5]	郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛. 醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2025, 43(3): 136-142, 150. doi: 10.12206/j.issn.2097-2024.202310043
[6]	陈方剑, 赵娟娟, 叶侃倜, 孙煜昕, 刘继勇, 杨骏. 血通胶囊提取工艺优化及质量控制研究 . 药学实践与服务, 2025, 43(2): 82-86, 91. doi: 10.12206/j.issn.2097-2024.202409003
[7]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[8]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
[9]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[10]	邹思, 吴岩斌, 吴锦忠, 吴建国, 黄家兴. 虎奶菇菌核多糖功能化纳米硒抗疲劳功效研究 . 药学实践与服务, 2024, 42(10): 426-432. doi: 10.12206/j.issn.2097-2024.202206072
[11]	凯丽比努尔·奥布力艾散, 李倩, 谢志, 贾文彦, 尹东锋. 星点设计-效应面法优化仑伐替尼混合胶束的制备工艺 . 药学实践与服务, 2024, 42(11): 495-502. doi: 10.12206/j.issn.2097-2024.202403019
[12]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[13]	赖立勇, 夏天爽, 徐圣焱, 蒋益萍, 岳小强, 辛海量. 中药青蒿抗氧化活性的谱效关系研究 . 药学实践与服务, 2024, 42(5): 203-210, 216. doi: 10.12206/j.issn.2097-2024.202211012

期刊类型引用(0)
其他类型引用(5)

点击查看大图

计量

文章访问数: 4259
HTML全文浏览量: 548
PDF下载量: 1261
被引次数: 5

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

doi: 10.3969/j.issn.1006-0111.2017.03.007

第二军医大学药学院, 上海 200433

基金项目: 国家自然科学基金资助项目（81573376）

收稿日期: 2017-01-18
修回日期: 2017-03-31

关键词:

阿霉素 /

依克立达 /

纳米粒 /

紫外分光光度法 /

高效液相色谱法

摘要: 目的建立药物测定方法，并制备共载阿霉素和依克立达的PLGA纳米粒。方法利用紫外分光光度法（UV）和高效液相色谱法（HPLC）分别建立阿霉素和依克立达的测定方法；采用纳米沉淀法制备共载纳米粒，通过调节两药的投药比，优化处方，考察纳米粒的粒径、形态、包封率、载药量以及体外释放。结果阿霉素在1~40 μg/ml浓度范围内线性关系良好，标准曲线回归方程为A=0.021C+0.002，r=0.999 5；依克立达在0.5~100 μg/ml浓度范围内线性关系良好，标准曲线回归方程为A=120 742.462 6C+1 974.570 4，r=1.000 0；通过处方优化，共载纳米粒的粒径约为50 nm，分布均一，呈圆形，阿霉素和依克立达的包封率分别为56.58%、51.66%，载药量分别为1.48%、1.85%，两药摩尔比约为1：1；体外释放缓慢。结论分别建立了方便快捷、结果准确、重复性好的阿霉素和依克立达的检测方法，并且制备了分散性好、粒径较小的纳米粒，为后续实验提供基础。

English Abstract

Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2017-01-18
Rev Recd Date: 2017-03-31

Keywords:

doxorubicin /
elacridar /
nanoparticles /
UV /
HPLC

Abstract: Objective To establish methods for the determination of doxorubicin and elacridar, and prepare PLGA nanoparticles for the co-delivery of doxorubicin and elacridar. Methods Ultraviolet spectrophotometry (UV) and high performance liquid chromatography (HPLC) were used to establish the determination method of doxorubicin and elacridar, respectively; co-delivery nanoparticles system was prepared by nanoprecipitation method, and optimizing the prescription was by adjusting the dosage ratio of the two drugs to investigate the particle size,morphology, encapsulation efficiency (EE), drug loading (DL) and in vitro release. Results The linearity of doxorubicin was better in the rang of 1 to 40 μg/ml, A=0.021C+0.002,r=0.999 5;the linearity of elacridar was better in the rang of 0.5 to 100 μg/ml,A=120 742.462 6C+1 974.570 4,r=1.000 0;the particle size was about 50 nm; transmission electron microscope (TEM) showed that nanoparticles were round in shape and had a good dispersion;EE of doxorubicin and elacridar were 56.58%、51.66%,respectively, DL of doxorubicin and elacridar were 1.48%、1.85%,respectively,the molar ratio of two drugs was about 1:1;the nanoparticles released slowly in vitro. Conclusion The established methods of doxorubicin and elacridar were convenient and efficient, accurate and repeatable.The Co-delivery nanoparticles system was well dispersionand smaller size, which could be used for further studies.